Scientific Conflict Of Interest Regulations Offer Loophole To Small Business Program

NIH takes aim at the links between industry and those doing clinical trials while ignoring firms that get funds for technology innovations WASHINGTON--Current government efforts to prevent financial conflicts of interest among clinical investigators appear to ignore an obscure but well-funded federal program that operates with few safeguards against such potential abuse by researchers. And some scientists think that omission could be a costly mistake. Officials at the National Institutes of

Written byJeffrey Mervis
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

WASHINGTON--Current government efforts to prevent financial conflicts of interest among clinical investigators appear to ignore an obscure but well-funded federal program that operates with few safeguards against such potential abuse by researchers. And some scientists think that omission could be a costly mistake.

Officials at the National Institutes of Health have just finished work on proposed rules for the biomedical community that are meant to balance the government's desire to turn basic research into commercial products against society's growing concern about the integrity of those who perform that research.

WASHINGTON--The Bush administration is unlikely to endorse any conflict of interest regulations that require clinical scientists to do anything more than disclose financial holdings in the companies whose products they are evaluating, according to White House officials. National Institutes of Health administrators have recently completed work on proposed guidelines that suggest a more stringent policy, and are awaiting approval from the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies